← ANALYST RATINGS · TIPRANKS
Neurogene (NGNE): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $84.20, the highest $166, the lowest $46.00. The average is +262.2% from the last price of $23.25.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $28.00 → $23.50−16.1% | Hold | +1.1% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $22.50−2.2% | Sell | −3.2% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $26.00 → $23.00−11.5% | Sell | −1.1% | Downgrade | 16.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $23.00−17.9% | Hold | −1.1% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $23.00−14.8% | Hold | −1.1% | Upgrade | 16.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $23.00−14.8% | Hold | −1.1% | Reiterated | 16.10.26on TipRanks 01:05 | — | |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $46.00 | Buy | +97.8% | Reiterated | 08.10.26on TipRanks 09:05 | +2.9%next day −1.0% · 5 days −9.3% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $60.00 | Buy | +158.1% | Initiated | 08.10.26on TipRanks 05:25 | +2.9%next day −1.0% · 5 days −9.3% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $180 → $166−7.8% | Buy | +614.0% | Reiterated | 12.08.26on TipRanks 07:20 | +3.0%next day −4.3% · 5 days +7.1% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $70.00 → $65.00−7.1% | Buy | +179.6% | Reiterated | 12.08.26on TipRanks 06:30 | +3.0%next day −4.3% · 5 days +7.1% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $69.00 → $81.00+17.4% | Buy | +248.4% | Reiterated | 11.08.26on TipRanks Aug 12 07:10 | −1.7%next day +3.0% · 5 days 0.0% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 01:20 | −1.7%next day +3.0% · 5 days 0.0% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 11.08.26on TipRanks 19:15 | +3.0%next day −4.3% · 5 days +7.1% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $65.00 → $63.00−3.1% | Buy | +171.0% | Reiterated | 11.08.26on TipRanks 13:14 | −1.7%next day +3.0% · 5 days 0.0% | ↗ |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $70.00 | Buy | +201.1% | Initiated | 03.06.26on TipRanks 07:11 | +1.0%next day +4.4% · 5 days +10.6% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | $65.00 | Buy | +179.6% | Reiterated | 15.05.26on TipRanks 09:35 | −3.4%next day −6.1% · 5 days −8.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Neurogene
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $84.20 at a price of $27.82 (+202.7%); now: $80.17 at $23.25 (+244.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 17 | 15 | 14 | 6 | 5 |
| Buy | 5 | 5 | 6 | 6 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 23.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.36 (from $-1.59 to $-0.96). Last quarter: $-1.53.
Best top-analyst consensus in the sector · Healthcare
About Neurogene
- CEO: Rachel L. McMinn
- Employees: 131
- 535 W 24th Street, New York City, NY, 10011, US
- www.neurogene.com
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗